| Clinuvel Pharmaceuticals Limited (CUV) ORDINARY FULLY PAID |
Health Care |
$516 |
Ceasing to be a substantial holder
|
13 Aug 2024 8:12AM |
$14.180 |
$10.300 |
fallen by
27.36%
|
|
| West Cobar Metals Limited (WC1) ORDINARY FULLY PAID |
Materials |
$5 |
Drilling Completed at Bulla Park Copper Project
|
13 Aug 2024 8:12AM |
$0.029 |
$0.024 |
fallen by
17.24%
|
|
WC1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Diamond drilling successfully completed at the Bulla Park Copper Project, NSW
- Approximately 218m of core from BPD09 is being cut and prepared for assay
- West Cobar Metals Limited (ASX: WC1) announced a further program of diamond drilling has been completed at the Bulla Park Copper Project
- Program consisted of 2 diamond holes totaling 547 meters
- Hole BPD09 intersected a broad zone of disseminated sulphides from 120m to 338m (218m)
- Hole BPD10 tested an airborne magnetic anomaly indicating a bed of maghemite within overlying alluvium
- Assay results expected during September
- WC1 will assess the Bulla Park Project with additional information and design further drilling
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sprintex Limited (SIX) ORDINARY FULLY PAID |
Consumer Discretionary |
$26 |
Sprintex Strategic Update and Investor Briefings
|
13 Aug 2024 8:12AM |
$0.046 |
$0.042 |
fallen by
8.70%
|
|
SIX - Price-sensitive ASX Announcement
Full Release
Key Points
- Sprintex has secured significant partnerships in Europe, Turkey, and China, with expected revenues of A$14.75 million from the China market alone.
- The G15 and G25 blower series feature state-of-the-art energy-efficient technology and intelligent control systems.
- Sprintex aims for a market capitalization of $100 million by June 2025 and $250 million by December 2026.
- The company is advancing in the clean energy sector with collaborations in the U.S. and Europe.
- Sprintex will host a series of investor and broker briefings to discuss strategic updates.
- Sprintex’s G Series blowers are designed for high-speed air movement in various industrial applications.
- The company also develops fuel cell compressors for clean energy applications, particularly in hydrogen and natural gas fuel cells.
- Sprintex focuses on enhancing hybrid and petrol vehicles with high-speed electric motor-driven compressors in the automotive sector.
- The company has a robust supply chain and manufacturing capabilities with facilities in China and Malaysia.
- Sprintex’s proprietary technologies are protected through in-house manufacturing and assembly.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| West African Resources Limited (WAF) ORDINARY FULLY PAID |
Materials |
$2,736 |
WAF Kiaka South surprises with 22m at 7.6 g/t gold
|
13 Aug 2024 8:11AM |
$1.325 |
$2.400 |
risen by
81.13%
|
|
WAF - Price-sensitive ASX Announcement
Full Release
Key Points
- West African Resources Limited (WAF) reported results from their maiden grade control drilling at Kiaka South pit.
- The Kiaka South pit is located 700m from Kiaka Main pit and is expected to deliver higher grade mill feed in the first 18 months of production.
- Significant drilling results include 22m at 7.6 g/t gold, 26m at 5.8 g/t gold, and 28m at 4.8 g/t gold, among others.
- Drilling at Kiaka South has intercepted thicker and higher grade zones closer to the surface than initially expected.
- WAF aims to optimize the Kiaka South open pit to increase grade and reduce the strip-ratio before mining starts in Q1 2025.
- Kiaka South is expected to produce 1Mt of ore at an average grade of 2.0 g/t Au during the first 18 months of ore production.
- WAF is on track to produce 4 million ounces of gold over the next decade with annual production peaking at 473,000 ounces in 2029.
- The company’s unhedged resources are at 12.8 million ounces with ore reserves at 6.1Moz of gold.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strike Energy Limited (STX) ORDINARY FULLY PAID |
Energy |
$487 |
SE Power Project Awarded Certified Reserve Capacity
|
13 Aug 2024 8:11AM |
$0.170 |
$0.170 |
fallen by
0%
|
|
STX - Price-sensitive ASX Announcement
Full Release
Key Points
- Strike has been awarded 85 MW of Certified Reserve Capacity in the South West Interconnected System by AEMO for the South Erregulla peaking gas power station.
- The CRC award is a significant milestone, de-risking the project as it heads towards a Final Investment Decision in November 2024.
- The awarded CRC and capacity credits are projected to generate annual revenues between $15-20 million.
- Development of the power project is contingent on the award of Network Access Quantity, satisfying project finance conditions, executing procurement contracts, and obtaining necessary permits by November 2024.
- Strike’s Managing Director, Stuart Nicholls, emphasized the integrated gas-to-power project’s role in supporting Western Australia’s energy transition.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Allegra Medical Technologies Limited (AMT) ORDINARY FULLY PAID |
Health Care |
- |
Change in substantial holding
|
13 Aug 2024 8:11AM |
$0.029 |
$0.029 |
fallen by
0%
|
|
| Geopacific Resources Ltd (GPR) ORDINARY FULLY PAID |
Materials |
$76 |
Mineral Resource increased to 1.67 Moz
|
13 Aug 2024 8:11AM |
$0.022 |
$0.024 |
risen by
9.09%
|
|
GPR - Price-sensitive ASX Announcement
Full Release
Key Points
- Total Woodlark Mineral Resource now stands at 1.67 Moz gold, comprising 48.3 Mt at 1.07 g/t Au.
- Increase due to historic drilling at Great Northern and Wayai Creek.
- New MREs provide potential for additional upside.
- New drill campaign targeting high-grade, near-surface mineralization.
- 87.6% of the resource in Measured and Indicated categories.
- The increase follows the recently reported Woodlark Scoping Study.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Earths Energy Limited (EE1) ORDINARY FULLY PAID |
Materials |
$3 |
Webinar - Harnessing Geothermal Energy
|
13 Aug 2024 8:11AM |
$0.014 |
$0.005 |
fallen by
64.29%
|
|
| Spheria Emerging Companies Limited (SEC) ORDINARY FULLY PAID |
Financials |
$144 |
Net Tangible Asset Backing
|
13 Aug 2024 8:10AM |
$2.150 |
$2.410 |
risen by
12.09%
|
|
| Good Drinks Australia Ltd (GDA) ORDINARY FULLY PAID |
Consumer Staple |
- |
FY24 Results Update
|
13 Aug 2024 8:10AM |
$0.280 |
$0.320 |
risen by
14.29%
|
|
GDA - Price-sensitive ASX Announcement
Full Release
Key Points
- Good Drinks Australia (GDA) announced unaudited FY24 results.
- Strong performance in both Core Business and Hospitality Business.
- Group EBITDA increased by 16% to $8.2 million.
- Own-brand volume grew by 10% to 15 million liters.
- Core Business EBITDA increased by 263% to $3.7 million.
- Partner brand volume up by 4% to 11.6 million liters.
- Hospitality Business EBITDA remained stable at $4.5 million.
- Total volume sold increased by 7% to 27.2 million liters.
- Significant own-brand growth in key markets like QLD (26%) and WA (11%).
- Overall retail beer market declined by 4.2% in volume.
- GDA's own brands maintained a 10-30% price premium over competitors.
- Matso's Sunshine Coast venue opened and trading well.
- Atomic Redfern venue is under divestment and fully impaired by $4.5 million as of June 30, 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Perenti Limited (PRN) ORDINARY FULLY PAID |
Materials |
$1,473 |
Details of FY24 Results Teleconference
|
13 Aug 2024 8:10AM |
$0.970 |
$1.585 |
risen by
63.40%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$8,646 |
Becoming a substantial holder
|
13 Aug 2024 8:10AM |
$17.990 |
$25.560 |
risen by
42.08%
|
|
| Smartgroup Corporation Ltd (SIQ) ORDINARY FULLY PAID |
Industrials |
$989 |
Ceasing to be a substantial holder
|
13 Aug 2024 8:10AM |
$8.410 |
$7.290 |
fallen by
13.32%
|
|
| Perseus Mining Limited (PRU) ORDINARY FULLY PAID |
Materials |
$5,366 |
Ceasing to be a substantial holder
|
13 Aug 2024 8:10AM |
$2.410 |
$3.930 |
risen by
63.07%
|
|
| Temple & Webster Group Ltd (TPW) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,704 |
Securities Trading Policy and Minimum Shareholding Policy
|
13 Aug 2024 8:09AM |
$9.500 |
$22.760 |
risen by
139.58%
|
|
| Temple & Webster Group Ltd (TPW) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,704 |
FY24 Investor Presentation
|
13 Aug 2024 8:09AM |
$9.500 |
$22.760 |
risen by
139.58%
|
|
TPW - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue for FY24 was $498 million, up 26% year over year.
- TPW increased its market share by 31% in a market that declined by 4%.
- Delivered margin increased by 29%, driven by improved shipping recovery and reduced refunds.
- Customer service costs and merchant fees decreased by 30% due to AI efficiencies.
- The company's first significant brand marketing investment was approximately $10 million.
- Fixed costs as a percentage of revenue decreased from 12% in FY23 to 11% in FY24.
- EBITDA margin of 2.6% (excluding one-off costs) within the target range of 1-3%.
- The company's goal is to reach $1 billion in annual sales in the mid-term.
- Trade & Commercial (B2B) revenue grew by 27%, and home improvement revenue grew by 26%.
- TPW is leveraging AI and internal development to create competitive advantages.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Temple & Webster Group Ltd (TPW) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,704 |
FY24 Results, Trading Update & CFO Appointment
|
13 Aug 2024 8:09AM |
$9.500 |
$22.760 |
risen by
139.58%
|
|
TPW - Price-sensitive ASX Announcement
Full Release
Key Points
- Record FY24 revenue of $498 million, up 26% year-on-year
- 31% increase in active customers to 1.1 million
- EBITDA (excluding one-off costs) of $13.1 million
- Free cash flow of $25 million
- Closing cash balance of $116 million with no debt
- Strong start to FY25 with 26% increase in trading
- 57% of all orders from repeat customers
- Addition of over 850 new private label products
- Introduction of advanced AI/data capabilities
- Appointment of Cameron Barnsley as CFO effective 2nd September 2024
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Temple & Webster Group Ltd (TPW) ORDINARY FULLY PAID |
Consumer Discretionary |
$2,704 |
Appendix 4E & Financial Report
|
13 Aug 2024 8:09AM |
$9.500 |
$22.760 |
risen by
139.58%
|
|
TPW - Price-sensitive ASX Announcement
Full Release
Key Points
- Record FY24 revenue of $497.8m, up 26% from the previous year.
- Active customer growth of 31%, reaching 1.1 million.
- Gross margin improved to 33.4% from 32.6% in FY23.
- EBITDA (pre-one-off costs) of $13.1m at 2.6% of revenue.
- Reduction in profit before tax to $6.4m from $12m due to reinvestment strategy.
- No dividends were paid, recommended, or declared during the financial year.
- The Group's impairment test showed no impairment charge required for TPW CGU.
- Significant market share increase of 31% despite a 4% decline in the furniture and homewares market.
- The Group holds 33% shares in Renovai, Inc., which has been fully impaired.
- Strong financial position with an ending cash balance of $116m and no debt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$117,141 |
CSL appoints new Non-Executive Director
|
13 Aug 2024 8:08AM |
$308.930 |
$241.920 |
fallen by
21.69%
|
|
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$117,141 |
Appendix 4G & Corporate Governance Statement
|
13 Aug 2024 8:08AM |
$308.930 |
$241.920 |
fallen by
21.69%
|
|
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$117,141 |
Results Presentation
|
13 Aug 2024 8:06AM |
$308.930 |
$241.920 |
fallen by
21.69%
|
|
CSL - Price-sensitive ASX Announcement
Full Release
Key Points
- CSL Behring's revenue grew by 14% to $10,608 million, driven by strong performance in immunoglobulin (Ig), albumin, and haemophilia therapies.
- CSL Seqirus experienced a 4% revenue increase, with notable growth in the FLUAD® influenza vaccine.
- CSL Vifor's notable achievements include robust EU iron volumes and strong nephrology launches, contributing to a total revenue of $2,128 million.
- The Rika plasma donation system was successfully rolled out to 84 centers, with full U.S. deployment expected by the end of FY25.
- CSL's NPATA increased by 15% to $3,008 million at constant currency.
- The gross margin improved by 120 basis points, attributed to factors such as plasma collection efficiencies and product mix improvements.
- CSL obtained regulatory clearances for several products including the I-Nomogram and HEMGENIX® infusions in Europe.
- Seqirus received regulatory approval for the world's first sa-mRNA COVID vaccine, KOSTAIVE®, in Japan.
- CSL Behring's key therapy areas such as Ig, albumin, and haemophilia showed significant growth, with Ig increasing by 20%.
- CSL projects revenue growth of 5-7% and NPATA growth of 10-13% for FY25, driven by strong demand and new product launches.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$117,141 |
Results Announcement
|
13 Aug 2024 8:05AM |
$308.930 |
$241.920 |
fallen by
21.69%
|
|
CSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Full year reported NPATA of US$2.91 billion, up 15% at constant currency
- Revenue was $14.8 billion, up 11% at constant currency
- Net profit after tax (NPAT) was $2.64 billion, up 20%
- CSL Behring performance was strong, particularly in the immunoglobulins portfolio
- CSL Seqirus outperformed the market with the adjuvanted influenza vaccine FLUAD®
- CSL Vifor continues to grow iron volume in Europe despite generic entrants
- Total revenue for CSL Behring was $10,608 million, up 14%
- Immunoglobulin product sales increased 20%
- Sales for PRIVIGEN®/INTRAGAM® grew 21%
- HIZENTRA® sales were up 19%
- Albumin sales were $1,209 million, up 12%
- Haemophilia product sales increased 10%
- IDELVION® achieved 10% growth, maintaining market leadership
- HEMGENIX® gene therapy treatment continues to gain momentum
- Specialty products sales were $1,940 million, up 6%
- Plasma collections momentum continued with reduced cost per litre
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$117,141 |
Dividend/Distribution - CSL
|
13 Aug 2024 8:05AM |
$308.930 |
$241.920 |
fallen by
21.69%
|
|
| CSL Limited (CSL) ORDINARY FULLY PAID |
Health Care |
$117,141 |
Full Year Statutory Accounts for 30 June 2024
|
13 Aug 2024 8:04AM |
$308.930 |
$241.920 |
fallen by
21.69%
|
|
CSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Profit after tax increased from $214.3 million in 2023 to $234.7 million in 2024.
- Total comprehensive income for the year increased from $204.0 million in 2023 to $217.2 million in 2024.
- Consolidated statement of financial position shows total current assets at $654.3 million and total non-current assets at $1,258.4 million as of 2024.
- Key assets include cash and cash equivalents, receivables, inventories, and property, plant, and equipment.
- Significant liabilities include trade and other payables, lease liabilities, rehabilitation and restoration provisions, and deferred tax liabilities.
- Corporate costs of Silver Lake Resources Limited are assessed to be in the range of $20 million to $25 million per annum.
- Revenue for the year to June 2023 was $719.6 million, with net profit after tax at $49.7 million.
- SLR has achieved consistent EBITDA margins between 35% and 44% over recent years.
- SLR's operations have generated positive cash from operating activities, with strong overall margins.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Challenger Limited (CGF) ORDINARY FULLY PAID |
Financials |
$5,400 |
2024 Corporate Governance Statement
|
13 Aug 2024 8:01AM |
$6.880 |
$7.810 |
risen by
13.52%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
